You are here

Home » Accelerator Programs » Innovation Grants

Innovation Grants

These grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. A Letter of Intent is required. The Innovation Award amount totals $250,000 over two years. The Award may not be renewed, however, one no cost extensions are allowable.

University of Texas Southwestern Medical Center

Background

We recently sequenced Wilms tumors, a childhood kidney cancer. We discovered a novel type of missense mutation at position G1809 in the enzyme DICER1, a critical part of the microRNA biogenesis machinery. This mutation, which appears to distort the geometry of the DICER1 active site, destroys the ability of DICER1 to produce the let-7 class of tumor-suppressing microRNAs.

Principal Investigator Name: 

James Amatruda, MD/PhD

Project Title: 

DICER1-Driven Cancers: Models, Mechanisms and Therapies

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

University of Rochester

Background

Acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer and relapsed ALL is the most common cause of death from childhood cancer. Exciting new research has shown that leukemia cells depend their survival on nonmalignant, noncancerous cells in the body.

Project Goal

Principal Investigator Name: 

Craig Mullen, MD/PhD

Project Title: 

Targeting Microenvironmental Support of Acute Lymphoblastic Leukemia

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Memorial Sloan-Kettering Cancer Center

Background

Neuroblastoma is the most frequently diagnosed cancer in infancy and accounts for 15% of all deaths due to childhood cancers. Recent progress has been made in therapies involving antibodies that recognize neuroblastoma cells and target them for destruction. Unfortunately, many children do not respond to the antibody therapy, because the immune cells that are responsible for killing the tumor are suppressed.

Project Goal

Principal Investigator Name: 

Katherine Hsu, MD/PhD & Nai-Kong Cheung, MD/PhD

Project Title: 

Development of an anti-KIR3DL1 Antibody to Promote Innate Immunity Against Neuroblastoma

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

University of California, San Diego

Background

Patients diagnosed with "high risk" neuroblastoma have a high rate of failure (death) even after aggressive drug treatment and bone marrow transplantation leaves most children "cured". In 2010, we reported on the efficacy of an antibody therapeutic ch14.18, which reduces disease recurrence to about 25%. In 2015, after a long clinical trial, ch14.18 (renamed dinutuximab) received FDA approval and is now available to treat children. Alas, while fewer children are dying, even one death from this disease is too many, never mind 25%!

Principal Investigator Name: 

Alice Yu, MD/PhD & Mitchell Diccianni, PhD

Project Title: 

Enhancing Immunotherapy of Neuroblastoma

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

MYC as a Driver and Anti-Cancer Target in Malignant Rhabdoid Tumors

Background

Malignant rhabdoid tumor, or MRT, is a rare but devastating childhood cancer. Most children diagnosed with MRT are under the age of two, and most will die from the disease despite intensive surgical, radiological, and chemotherapeutic interventions. A sad reality of MRT is that it is such a rare cancer that drug companies have little interest in developing new ways to treat the disease, meaning that a dismal prognosis is all we can hope to offer the two dozen children who are diagnosed with MRT in the United States every year.

Principal Investigator Name: 

William Tansey, PhD

Project Title: 

MYC as a Driver and Anti-Cancer Target in Malignant Rhabdoid Tumors

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Pennsylvania State University

Background

High-risk B-cell acute lymphoblastic leukemia (B-ALL) frequently recurs after initial treatment and is a lethal disease. "Ikaros" is a cancer fighting protein that prevents leukemia from developing. In children who are diagnosed with high-risk B-ALL, the activity of Ikaros in leukemia cells has been impaired by another protein called CK2. By using a novel medicine that can block the effects of CK2, our laboratory has found that we can restore the cancer fighting ability of Ikaros and kill leukemia cells.

Project Goal

Principal Investigator Name: 

Sinisa Dovat, MD/PhD & Chunhua Song, MD/PhD

Project Title: 

Targeted Combination Therapy to Sensitize High-Risk Acute Lymphoblastic Leukemia to Methotrexate via Restoration of Ikaros Tumor Suppression

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

The Cleveland Clinic Foundation

Background

Rhabdomyosarcomas are a rare but aggressive type of cancer in children and adolescents. There are approximately 350 new diagnoses of childhood RMS in the United States per year. The outcomes for high-risk patients with this disease have not significantly improved in the last several decades and survival of metastatic or relapsed disease remains extremely poor. In rhabdomyosarcoma the tumor cells resemble dividing muscle cells.

Project Goal

Principal Investigator Name: 

Neetu Gupta, PhD & Peter Anderson, MD

Project Title: 

Targeting the Function of Ezrin in Rhabdomyosarcoma

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Johns Hopkins University

Background

Medulloblastoma is the most common pediatric brain tumor. While up to 80% of patients are cured, there is a subgroup of patients for whom the current aggressive therapies do not work. These patients have tumors which make large amounts of a protein called MYC. This is a very strong driver of cancer cell growth, but MYC is very hard to target directly.

Project Goal

Principal Investigator Name: 

Eric Raabe, MD/PhD & Dr. Barbara Slusher, PhD

Project Title: 

Pre-clinical Testing of Novel Glutamine Metabolic Inhibitors in MYC-driven Medulloblastoma

Year Awarded: 

2016

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Pages

Featured Hero

Alex Schnarre

Alex's cold seemed to be more than just a cold. He wasn't acting like himself, and his face and belly were swollen. Alex was diagnosed with AML and his kidneys were in acute failure, so he began treatment immediately. Today, he is thriving!
Read more »